SCHEMBL5318685

SCHEMBL5318685

Nc1cc(Oc2ccnc(Cl)n2)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.43
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 2/20 0.38
GAA P10253 1/20 0.38
SCN9A Q15858 5/20 0.38
KDR P35968 2/20 0.37
POLB P06746 2/20 0.37
CASP6 P55212 1/20 0.37
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
SCN5A Q14524 2/20 0.35
NR4A1 P22736 1/20 0.35
MET P08581 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PLAAT3 P53816 1/20 0.34
PLAAT5 Q96KN8 1/20 0.34
PLAAT2 Q9NWW9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5442271 0.88 MAP4K4 (0.43) MAP4K4MEN1KMT2AHTTGAA
SCHEMBL2025837 0.86 KDR (0.45) MAP4K4MEN1KMT2ASCN9AKDR
SCHEMBL19510741 0.86 MAP4K4 (0.49) MAP4K4MEN1KMT2AHTTGAA
SCHEMBL16654773 0.81 KDM4E (0.39) MAP4K4MEN1KMT2AHTTGAA
SCHEMBL2028873 0.80 HTT (0.55) MAP4K4MEN1KMT2AHTTGAA
SCHEMBL23943329 0.79 KDR (0.41) MAP4K4KMT2AHTTGAAKDR
SCHEMBL8688694 0.79 KDR (0.45) HTTGAAKDRFLT1FLT4
SCHEMBL5397064 0.79 MET (0.39) MAP4K4MEN1KMT2AALOX5APFEN1
SCHEMBL4938557 0.79 KDM4E (0.47) MAP4K4MEN1KMT2AHTTGAA
SCHEMBL4929568 0.78 KDR (0.47) MEN1KMT2AHTTGAASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 MAP4K4 69/4885MEN1 4271/4885KMT2A 3676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.